Sarah Amele Research Department of Infection and Population Health University College London Tel: +44 20 7794 0500 Ext 34611 sarah.amele.16@ucl.ac.uk

Regional Differences across Europe in Advanced Fibrosis and Cirrhosis among HIV/HCV Co-infected Persons between 2010-2015

S Amele¹, L Peters², JD Lundgren².³, JK Rockstroh⁴, H Sambatakou⁵, T Staub⁶, F Maltez², C Leen⁶, C Pedersen⁶, JM Gatell
Artigas¹⁰, S Moreno¹¹, R Matulionyte¹², G Kyselyova¹³, I Karpov¹⁴, D Jilich¹⁵, M Parczewski¹⁶, K Zilmer¹², H Elinav¹⁶,
K Lacombe¹⁶, M Cavassini²⁰, J Tomazic²¹ and A Mocroft¹ on behalf of the EuroSIDA study group

¹Department of Infection and Population Health, University College London, London, UK. ²Copenhagen HIV Programme, Faculty of Health Science, University of Copenhagen, Denmark. ³Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. ⁴Universitäts Klinik Bonn, Germany. ⁵Hippokration General Hospital, Greece. ⁶Centre Hospitalier de Luxembourg, ⁷Hospital Curry Cabral, Portugal. ⁸Western General Hospital, United Kingdom. ⁹Odense University Hospital Sundspital, Forskningsenheden Denmark. ¹⁰Hospital Clínic, Spain. ¹¹Hospital Ramon y Cajal, Spain. ¹²Vinition Sinition (¹Vinition Sinition Central Hospital Saint Antoine, ¹²Pomeramian Academy of Medicine (PAM), Poland. ¹Vinition Central Hospital, Estonia. ¹⁸Hadassah Hospital, Israel. ¹⁹Hospital Saint Antoine, France. ²⁰Centre hospitalier Universitaire Vaudois, Switzerland. ²University Clinical Centre Ljubljana, Slovenia.

BACKGROUND

The increasing availability of directly acting antivirals (DAAs) for the treatment of hepatitis C coinfected persons has in some countries led to targeting DAAs to those most at need (fibrosis ≥F3) because of their cost. The prevalence of fibrosis ≥F3 across Europe is largely unknown, nor is the extent to which it is changing in different regions of Europe.

AIMS:

- To investigate regional differences in the prevalence of fibrosis ≥F3 or liver events in persons
 co-infected with HIV/HCV.
- To investigate factors associated with developing fibrosis ≥F3 and how this changes over time across different regions.

METHODS:

- Individuals co-infected with chronic HCV (defined as being HCV-AB positive and HCV-RNA positive) with a liver fibrosis biomarker (liver biopsy, APRI, hyaluronic acid or FibroScan) result whilst under follow-up in EuroSIDA on January 1st each year from 2010 to 2015 were included in this study.
- The proportion of HCV-RNA positive patients with fibrosis METAVIR ≥F3 or liver events (hepatic decompensation, hepatocellular carcinoma) was compared between regions over time. Fibrosis ≥F3 was defined by:

Liver fibrosis biomarker	Result		
Liver biopsy	≥F3		
APRI	score ≥1.75		
Hyaluronic acid	>250ng/mL		
FibroScan	≥9kPa		

Adjusted odds ratio of an individual having fibrosis ≥F3 was assessed using logistic regression.
Generalised estimating equations were used to allow the inclusion of individuals under followup in multiple years. This method was also used to investigate the effect of time within each
region on the odds of developing fibrosis ≥F3.

RESULTS:

- There were 3712 individuals with chronic HCV and a liver fibrosis biomarker in the study, 965 of which had fibrosis ≥F3 at some point during follow-up (characteristics of patients shown in Table 1). 1411, 1367, 1317, 1382, 1371 and 2121 persons were under follow-up on 1/1/2010-2015 respectively
- The proportion of individuals with fibrosis ≥F3 under follow-up on 1/1/2010-2015 was 20.3%, 22.9% 21.3% 20.4% 20.4% and 23.0% respectively (**Figure 1**); with significant differences between regions each year (p<0.0001).
- The greatest increase over time was in Northern and Southern Europe (17.0% to 23.5% and 26.5% to 34.5%).
- 4.8%, 4.6%, 4.5%, 4.2%, 3.3% and 2.8% of persons under follow-up on 1/1/2010-2015 (respectively) experience a liver-related event.
- The proportion reporting testing HCV positive recently (<5 years) was low, and significantly differed between regions (p<0.0001), as did the median duration of HCV infection, 14 and 7 years in Southern/Eastern Europe respectively (p<0.0001); 15% of those testing positive recently had fibrosis ≥F3.
- After adjustment, non-MSM individuals had higher odds of fibrosis ≥F3 compared to MSM, as
 did individuals aged >50 compared to those aged 30-40. Compared to Southern Europe, all
 regions had lower odds of fibrosis ≥F3, as did those with CD4 count >200/mm³ (Figure 2).
- The change over time in fibrosis ≥F3 differed between regions (p=0.025). After adjustment, the odds of fibrosis ≥F3 was increasing in Southern Europe over time and showed an early increase before 2014-2015 in Northern Europe, with few changes over time in other regions (Figure 3).


LIMITATIONS:


- Not every individual had information on the date they were diagnosed, therefore detailed analysis of late presenters was not feasible.
- The proportion of patients with a liver-related event was also small, which precluded regional comparisons.


CONCLUSIONS:

26% of individuals with HIV/HCV had fibrosis ≥F3, with significant differences between regions likely attributable to duration of HCV infection. The odds of developing fibrosis ≥F3 was increasing by a small amount each year, with the most marked increases in Southern Europe. Although recent HCV diagnoses were uncommon, there was still a considerable proportion of recently diagnosed individuals with fibrosis ≥F3. The prevalence of fibrosis ≥F3 and the relationship between CD4 and fibrosis ≥F3 highlights the need to prioritise HIV and HCV screening, linkage to care and treatment across Europe. If for any reason HCV cannot be treated, the relationship between CD4 count and fibrosis ≥F3 also highlights the importance of encouraging patients to start ART while waiting for HCV treatment, to maintain HIV suppressions and increase their CD4 cell count.

		Overall total N=3712 n (%)	Fibrosis	
			<f3 N=2747</f3 	≥F3 N=965
			n (%)	n (%)
Region of Europe	South	1148 (30.9)	728 (26.5)	420 (43.5)
	Central - West	768 (20.7)	596 (21.7)	172 (17.8)
	North	595 (16.0)	429 (15.6)	166 (17.2)
	Central - East	579 (15.6)	464 (16.9)	115 (11.9)
	East	622 (16.8)	530 (19.3)	92 (9.5)
Age group	<30	402 (10.8)	359 (13.1)	43 (4.5)
	30-40	1057 (28.5)	840 (30.6)	217 (22.5)
	40-50	1292 (34.8)	893 (32.5)	399 (41.3)
	>50	961 (25.9)	655 (23.8)	306 (31.7)
*CD4 count (cells/mm³)	<200	572 (15.4)	329 (12.0)	243 (25.2)
	>200	3046 (82.1)	2353 (85.7)	693 (71.8)
*HIV-RNA (cp/ml)	<500	2986 (80.4)	2258 (82.2)	728 (75.4)
	500-10000	255 (6.9)	180 (6.6)	75 (7.8)
	>10000	387 (10.4)	262 (9.5)	125 (13.0)
Hepatitis C risk group	MSM [†]	519 (14.0)	416 (15.1)	103 (10.7)
	non-MSM	3193 (86.0)	2331 (84.9)	862 (89.3)
*Hepatitis B coinfected	No	2906 (78.3)	2172 (79.1)	734 (76.1)
	Yes	142 (3.8)	99 (3.6)	43 (4.5)
Gender	Male	2650 (71.4)	1909 (69.5)	741 (76.8)
	Female	1062 (28.6)	838 (30.5)	224 (23.2)
*cART	No	189 (5.1)	153 (5.6)	36 (3.7)
	Yes	3523 (94.9)	2594 (94.4)	929 (96.3)
*AIDS	No	2718 (73.2)	2044 (74.4)	674 (69.8)
	Yes	994 (26.8)	703 (25.6)	291 (30.2)
*HCV-RNA (IU/ml)	<500,000	1337 (36.0)	1015 (36.9)	322 (33.4)
	>500.000	2154 (58.0)	1558 (56.7)	596 (61.8)







EuroSIDA study group: http://www.chip.dk/Studies/EuroSIDA/Study-group
Download poster at: www.chip.dk

UCL